Previously Funded Subawards

2017

Atlas Genetics Ltd., (now Binx Health) a UK-based healthcare company focused on providing rapid diagnostics, was awarded a contract to adapt their testing platform for a multiplexed assay to diagnose chlamydia, gonorrhea, trichomonas, and *M. genitalium*.

2016

Three organizations received funding to advance the development of point-of-care devices:

Jonathan Posner, PhD at **University of Washington** was awarded a contract on to adapt his colorimetric Lateral Flow Isotachophoresis Diagnostic (LID) assay for high sensitivity detection of *Chlamydia trachomatis*.

Andrea Pais, MS, founder of **Novel Microdevices, LLC**, located in Annapolis, Maryland, was awarded a contract on to develop their sample-to-result device using advanced microfluidics for detection of *Chlamydia trachomatis* nucleic acid.

Andrew Ellington, PhD at **University of Texas at Austin** (UT) was awarded a contract to develop a cell phone attachment to carry out fluorescent detection of chlamydia nucleic acid using UT's proprietary OSD-LAMP assay.

2015

Balakrishnan Raja, PhD, Co-founder and R&D Director of **Luminostics, Inc.,** whose headquarters are located in Houston, Texas, and **Richard Willson, PhD** at the **University of Houston** in Houston, Texas, were awarded a contract to develop a smartphone-based point-of-care test for the diagnosis of *Chlamydia trachomatis* infections from vaginal swabs and urine using their proprietary "nanophosphors" in a lateral flow test device.

Sally McFall, PhD at **Northwestern University**, located in Evanston, Illinois, was awarded a contract to support the adaptation of an FDA-approved platform from a commercial source to create a new point-of-care test for chlamydia and to develop a method to extract swabs and urine for use with this platform.

2014

Lavance Northington, MBA and Chief Executive of **Cellgen Diagnostics**, whose headquarters are located in Irvine, California, was awarded a contract to develop a point-of-care test for chlamydia on its genetic microarray platform capable of multiplex analysis for chlamydia.

James Mahony, PhD at **McMaster University,** located in Ontario, Canada, was awarded a contract to integrate the Paratus Sample Delivery System with their proprietary LAMP assay to create a hand-held sample-to-result point-of-care test for chlamydia.

John Carrano, PhD and CEO of **Paratus Diagnostics LLC**, whose headquarters are located in Austin, Texas, was awarded a contract to develop their Specimen Delivery System (SDS™) for integration with a detection platform for chlamydia. The device extracts, lyses and delivers protein or clean nucleic acid for amplification as needed by the detection platform.

2012

Atlas Genetics Ltd., (now Binx Health) a UK-based healthcare company focused on providing rapid DNA diagnostics, was awarded a contract to adapt their testing platform into a point-of-care system for diagnosis of chlamydia infections.

2011

Meso Scale Diagnostics LLC, whose headquarters are located in Gaithersburg, Maryland, was awarded a contract to adapt their diagnostic testing platform into a point-of-care system for diagnosis of chlamydia infections. This award for development of a novel point-of-care test was made based on a review by a team of experts in the fields of medical technology, sexually transmitted disease and fieldable diagnostics.

2009

An award issued under the American Recovery and Reinvestment Act (ARRA) of 2009 was sub-contracted to **Diane R. Blake, MD** at the University of Massachusetts Medical School. Dr Blake and graduate student **Wei (Tiffany) Huang**, in collaboration with Dr. Gaydos, developed a comparative-effectiveness research (CER) model for clinic-based point-of-care Chlamydia tests versus standard Chlamydia tests, and for Internet-based POC and standard tests versus clinic-based POC and standard tests. Outcomes of this CER project provide guidance to public health officials for future recommendations of the most effective manner in which to address the chlamydia epidemic and prevent its sequelae.